To include your compound in the COVID-19 Resource Center, submit it here.

NovaMed Pharmaceuticals Inc., SciClone deal

SciClone acquired Chinese pharmaceutical company NovaMed in a cash and stock deal valued at $62.6 million based on SciClone's close

Read the full 201 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE